IRIS - Res&Arch Institutional Research Information System - Research & Archive

GAETANI, LORENZO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.378
AS - Asia 2.064
EU - Europa 1.402
SA - Sud America 322
AF - Africa 62
OC - Oceania 8
Totale 6.236
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.320
SG - Singapore 999
IT - Italia 314
CN - Cina 299
HK - Hong Kong 273
BR - Brasile 243
IE - Irlanda 223
RU - Federazione Russa 208
VN - Vietnam 139
DE - Germania 127
FR - Francia 99
KR - Corea 76
SE - Svezia 75
FI - Finlandia 71
GB - Regno Unito 61
IN - India 54
BD - Bangladesh 37
NL - Olanda 35
CA - Canada 28
JP - Giappone 27
TR - Turchia 27
RO - Romania 26
AR - Argentina 24
UA - Ucraina 23
PL - Polonia 22
IQ - Iraq 21
ZA - Sudafrica 20
AT - Austria 19
BE - Belgio 19
CZ - Repubblica Ceca 18
ID - Indonesia 16
UZ - Uzbekistan 15
PK - Pakistan 14
CO - Colombia 13
SA - Arabia Saudita 13
MX - Messico 12
VE - Venezuela 11
EC - Ecuador 10
ES - Italia 10
GR - Grecia 9
HR - Croazia 9
PH - Filippine 9
MA - Marocco 8
TN - Tunisia 7
PY - Paraguay 6
AE - Emirati Arabi Uniti 5
CL - Cile 5
KZ - Kazakistan 5
LT - Lituania 5
NZ - Nuova Zelanda 5
PT - Portogallo 5
AZ - Azerbaigian 4
CH - Svizzera 4
EG - Egitto 4
JM - Giamaica 4
KE - Kenya 4
NI - Nicaragua 4
UY - Uruguay 4
DK - Danimarca 3
DZ - Algeria 3
ET - Etiopia 3
GE - Georgia 3
IR - Iran 3
JO - Giordania 3
KG - Kirghizistan 3
LB - Libano 3
PA - Panama 3
AL - Albania 2
BG - Bulgaria 2
BO - Bolivia 2
GM - Gambi 2
GY - Guiana 2
HN - Honduras 2
IS - Islanda 2
MD - Moldavia 2
NO - Norvegia 2
NP - Nepal 2
OM - Oman 2
PE - Perù 2
SD - Sudan 2
SK - Slovacchia (Repubblica Slovacca) 2
TW - Taiwan 2
AF - Afghanistan, Repubblica islamica di 1
AO - Angola 1
AU - Australia 1
BA - Bosnia-Erzegovina 1
BB - Barbados 1
BF - Burkina Faso 1
BY - Bielorussia 1
BZ - Belize 1
CM - Camerun 1
CR - Costa Rica 1
CY - Cipro 1
HT - Haiti 1
KW - Kuwait 1
LA - Repubblica Popolare Democratica del Laos 1
LK - Sri Lanka 1
LU - Lussemburgo 1
LV - Lettonia 1
MM - Myanmar 1
Totale 6.222
Salva come PNG Salva come JPEG
Città #
Singapore 743
San Jose 279
Hong Kong 264
Chandler 257
Dublin 222
Ashburn 218
Perugia 145
Boardman 123
Santa Clara 89
Moscow 85
Seoul 76
Los Angeles 73
Beijing 70
Lauterbourg 69
Munich 69
San Mateo 69
Altamura 59
Des Moines 43
New York 43
Medford 40
Princeton 40
Andover 39
Lawrence 39
Ann Arbor 38
Ho Chi Minh City 37
Hanoi 36
Piscataway 35
The Dalles 35
Wilmington 35
Helsinki 31
Turku 26
Redmond 24
São Paulo 23
Denver 22
Tokyo 22
Boston 21
Chennai 21
Amsterdam 19
Brooklyn 19
Houston 19
Redwood City 18
Orem 17
Nuremberg 16
Rome 16
Frankfurt am Main 15
Montreal 15
Phoenix 15
Stockholm 15
Brussels 14
Vienna 14
Warsaw 14
Chicago 13
Falls Church 13
Brno 12
Dallas 12
Johannesburg 12
London 12
Manchester 12
Milan 12
Tashkent 11
Atlanta 10
Council Bluffs 10
Poplar 10
Rio de Janeiro 10
Timisoara 10
Haiphong 9
San Francisco 9
Seattle 9
Columbus 8
Hefei 8
Zagreb 8
Baghdad 7
Fairfield 7
Lappeenranta 7
Belo Horizonte 6
Bucharest 6
Da Nang 6
Falkenstein 6
Guangzhou 6
Lahore 6
New Delhi 6
Norwalk 6
Saint Petersburg 6
Secaucus 6
Ankara 5
Auckland 5
Campinas 5
Dong Ket 5
Quito 5
Riyadh 5
Woodbridge 5
Bogotá 4
Caracas 4
City of London 4
Dhaka 4
Florence 4
Istanbul 4
Izmir 4
Managua 4
Medellín 4
Totale 4.148
Salva come PNG Salva come JPEG
Nome #
CSF and blood biomarkers for Parkinson's disease 198
Positive allosteric modulation of indoleamine 2,3-dioxygenase 1 restrains neuroinflammation 150
Synaptic plasticity and experimental autoimmune encephalomyelitis: implications for multiple sclerosis 148
Microglial activation and the nitric oxide/cGMP/PKG pathway underlie enhanced neuronal vulnerability to mitochondrial dysfunction in experimental multiple sclerosis 139
Cerebrospinal fluid free light chains compared to oligoclonal bands as biomarkers in multiple sclerosis 138
CSF and Blood Biomarkers in Neuroinflammatory and Neurodegenerative Diseases: Implications for Treatment 125
A new enzyme-linked immunosorbent assay for neurofilament light in cerebrospinal fluid: analytical validation and clinical evaluation 122
Cerebrospinal fluid neurofilament light chain tracks cognitive impairment in multiple sclerosis 121
2017 revisions of McDonald criteria shorten the time to diagnosis of multiple sclerosis in clinically isolated syndromes 114
Visual pathway involvement in multiple sclerosis: Look straight in the eyes 113
Interleukin-17 affects synaptic plasticity and cognition in an experimental model of multiple sclerosis 113
Extracranial Venous Drainage Pattern in Multiple Sclerosis and Healthy Controls: Application of the 2011 Diagnostic Criteria for Chronic Cerebrospinal Venous Insufficiency 108
Lower urinary tract symptoms and urodynamic dysfunction in clinically isolated syndromes suggestive of multiple sclerosis 106
Cognitive impairment in multiple sclerosis: lessons from cerebrospinal fluid biomarkers 101
Psychiatric symptoms in multiple sclerosis: a biological perspective on synaptic and network dysfunction 98
CSF neurochemical profile and cognitive changes in Parkinson's disease with mild cognitive impairment 96
Treatment of multiple sclerosis relapses with high-dose methylprednisolone reduces the evolution of contrast-enhancing lesions into persistent black holes 96
Cerebrospinal fluid and serum D-serine concentrations are unaltered across the whole clinical spectrum of Alzheimer's disease 94
A microbially produced AhR ligand promotes a Tph1-driven tolerogenic program in multiple sclerosis 93
Cerebrospinal fluid levels of proenkephalin and prodynorphin are differentially altered in Huntington's and Parkinson's disease 93
Retinopathy during interferon-β treatment for multiple sclerosis: case report and review of the literature 89
Host and Microbial Tryptophan Metabolic Profiling in Multiple Sclerosis 86
Headache and immunological/autoimmune disorders: a comprehensive review of available epidemiological evidence with insights on potential underlying mechanisms 85
Molecular profiling in Parkinsonian syndromes: CSF biomarkers 84
Synaptic dysfunction in multiple sclerosis: A red thread from inflammation to network disconnection 82
Cerebrospinal fluid neurofilament light chain predicts disease activity after the first demyelinating event suggestive of multiple sclerosis 81
Insights into the pathophysiology of psychiatric symptoms in central nervous system disorders: Implications for early and differential diagnosis 81
Tracing Neurological Diseases in the Presymptomatic Phase: Insights From Neurofilament Light Chain 79
α-Synuclein Seed Amplification Assays for Diagnosing Synucleinopathies: The Way Forward 79
Clinical and diagnostic implications of Alzheimer's disease copathology in Lewy body disease 78
High performance liquid chromatography determination of L-glutamate, L-glutamine and glycine content in brain, cerebrospinal fluid and blood serum of patients affected by Alzheimer's disease 78
High risk of early conversion to multiple sclerosis in clinically isolated syndromes with dissemination in space at baseline 78
Neuroinflammation and Alzheimer's Disease: A Machine Learning Approach to CSF Proteomics 78
The no evidence of disease activity (NEDA) concept in MS: impact of spinal cord MRI 77
The Challenge of Disease-Modifying Therapies in Parkinson's Disease: Role of CSF Biomarkers. 76
Blood biomarkers may distinguish among dementia disorders 76
Cerebrospinal fluid β-synuclein as a synaptic biomarker for preclinical Alzheimer's disease 76
Investigating alpha-synuclein co-pathology in Alzheimer's disease by means of cerebrospinal fluid alpha-synuclein seed amplification assay 75
Recurrent hyperCKemia with normal muscle biopsy in a pediatric patient with neuromyelitis optica 75
Neurofilament light chain as a biomarker in neurological disorders 75
Impact of post-contrast MRI in the definition of active multiple sclerosis 74
Does cerebrospinal fluid neurofilament light chain correlate with psychiatric symptoms severity in multiple sclerosis? 74
Finding a way to preserve mitochondria: New pathogenic pathways in experimental multiple sclerosis 72
Potential diagnostic value of CSF metabolism-related proteins across the Alzheimer's disease continuum 71
Trajectories of CSF and plasma biomarkers across Alzheimer's disease continuum: Disease staging by NF-L, p-tau181, and GFAP 71
Multiple sclerosis and chronic progressive external ophthalmoplegia associated with a large scale mitochondrial DNA single deletion 71
Biomarker-Based Prediction of Parkinson Disease: Time for a Shift in Neurologists' Attitude Toward Neurodegenerative Diseases 69
Author Response: NfL as Analogue of C-Reactive Protein in Neurologic Diseases: Instructions for Use 68
Serum neurofilament light chain as a preclinical marker of neurodegeneration 67
CSF synaptic biomarkers and cognitive impairment in multiple sclerosis 66
Association between Neuropsychological Performance and CSF Profile in Subjective Cognitive Decline: Towards the Diagnosis of Preclinical AD 66
Phosphatidylethanolamine Binding Protein 1 (PEBP1) in Alzheimer's Disease: ELISA Development and Clinical Validation 66
Aquaporin-4 as a cerebrospinal fluid biomarker of Alzheimer’s disease 66
Alpha and Beta Synucleins: From Pathophysiology to Clinical Application as Biomarkers 66
Intrathecal B cell activation and memory impairment in multiple sclerosis 65
Infliximab monotherapy for neuro-Behçet's disease: a case report 65
Defining the course of tumefactive multiple sclerosis: A large retrospective multicentre study 65
A blood test for Alzheimer's disease: a step forward 64
CSF Synaptic Biomarkers in AT(N)-Based Subgroups of Lewy Body Disease 63
Post-contrast MRI in multiple sclerosis: Towards a judicious use of gadolinium-based contrast agents 63
Cerebrospinal fluid interferon-γ and development of depression in multiple sclerosis 62
Clinical correlates of state and trait anxiety in multiple sclerosis 62
Immunoassay detection of multiphosphorylated tau proteoforms as cerebrospinal fluid and plasma Alzheimer’s disease biomarkers 59
Lower urinary tract symptoms and urodynamic dysfunctions in clinically isolated syndromes suggestive of multiple sclerosis. 59
Methods to discover and validate biofluid-based biomarkers in neurodegenerative dementias 58
CSF neurosecretory proteins VGF and neuroserpin in patients with Alzheimer's and Lewy body diseases 58
The Immune Signature of CSF in Multiple Sclerosis with and without Oligoclonal Bands: A Machine Learning Approach to Proximity Extension Assay Analysis 58
LRRK2 Quantification in Cerebrospinal Fluid of Patients with Parkinson's Disease and Atypical Parkinsonian Syndromes 57
Required improvements for cerebrospinal fluid-based biomarker tests of Alzheimer's disease 56
Fully automated measurement of plasma Aβ42/40 and p-tau181: Analytical robustness and concordance with cerebrospinal fluid profile along the Alzheimer's disease continuum in two independent cohorts 55
Machine Learning Driven Profiling of Cerebrospinal Fluid Core Biomarkers in Alzheimer's Disease and Other Neurological Disorders 54
CSF and plasma Aβ42/40 across Alzheimer's disease continuum: comparison of two ultrasensitive Simoa® assays targeting distinct amyloid regions 53
CSF biomarkers of B-cell activation in multiple sclerosis: a clinical perspective 51
Increased plasma DOPA decarboxylase levels in Lewy body disorders are driven by dopaminergic treatment 49
Research advancement in fluid biomarkers for Parkinson's disease 45
SARS-CoV-2 vaccines tolerability: A perspective by people with multiple sclerosis 40
Diagnostic value of kappa free light chain index in patients with primary progressive multiple sclerosis – a multicentre study 40
Hippocampal neuroplasticity and inflammation: Relevance for multiple sclerosis 35
Fluid biomarkers in multiple sclerosis: from current to future applications 33
Immune profiling unveils the systemic cytokine milieu associated with acute reversible encephalopathy with cytotoxic lesions of the corpus callosum (CLOCCs) 19
Blood-based biomarkers for Alzheimer’s disease: influence of kidney function 16
Influence of co-pathology on CSF and plasma synaptic markers SNAP25 and VAMP2 in Alzheimer’s disease and Parkinson’s disease 15
Phosphorylated α-synuclein in CSF and plasma does not reflect synucleinopathy 13
Cerebrospinal fluid α-synuclein seed amplification assay positivity is associated with increased plasma neurofilament light chain in Alzheimer's disease 13
Transcriptome analysis of the prefrontal cortex identifies inflammatory genes associated with cognitive impairment in a model of multiple sclerosis 10
Prognostic value of kappa free light chain index in patients with primary progressive multiple sclerosis 7
Totale 6.383
Salva come PNG Salva come JPEG
Categoria #
all - tutte 27.696
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 27.696
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202118 0 0 0 0 0 0 0 0 0 5 6 7
2021/2022380 3 49 12 12 26 10 5 93 17 46 61 46
2022/2023858 45 184 15 68 62 104 4 38 302 1 26 9
2023/2024511 24 54 15 11 7 2 97 20 68 26 80 107
2024/20251.392 13 108 69 75 122 103 95 139 239 85 220 124
2025/20262.896 205 239 128 412 430 300 503 157 298 224 0 0
Totale 6.383